What is the occurrence range of warfarin embryopathy?

The occurrence range of warfarin embryopathy is recognized to be between 2-30%. Warfarin is an anticoagulant medication that is often used during pregnancy in specific cases but can pose risks to fetal development. Warfarin embryopathy typically arises from first-trimester exposure, where it can lead to various structural anomalies including facial dysmorphism, skeletal abnormalities, and central nervous system issues such as agenesis of the corpus callosum. The broad range of 2-30% reflects variability based on factors such as the timing of exposure, dosage, patient genetics, and the presence of other risk factors.

Understanding this occurrence range is essential for healthcare providers when considering management strategies for pregnant patients requiring anticoagulation. Identifying potential risks associated with fetal exposure enables better counseling on the risks and benefits of continuing or switching medications during pregnancy.